Robert Lorne Hopfner, Director at Inozyme Pharma, Inc. (INZY), bought 1,070,000 shares at $3.69 ($3.9M) on 2022-04-19, disclosed to the SEC on 2022-04-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| INZY | BUY | 2023-05-15 | $5.7M | — | Filing → |
| INZY | BUY | 2023-03-30 | $3.1M | — | Filing → |
| INZY | BUY | 2023-03-29 | $1.7M | — | Filing → |